Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q4 FY21 results · Jan–Mar 2021
Divi's Laboratories reported revenue from operations of ₹1,788.19 crore (up 28.7% from Q4 FY20) and net profit of ₹502.02 crore (up 29.3% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,788.19 | 1,389.71 | +28.7% | 1,701.44 | +5.1% |
| Other income | 23.52 | 76.73 | −69.3% | 19.32 | +21.7% |
| Total income | 1,811.71 | 1,466.44 | +23.5% | 1,720.76 | +5.3% |
| Profit before tax | 669.49 | 470.96 | +42.2% | 642.08 | +4.3% |
| Net profit for the period | 502.02 | 388.23 | +29.3% | 470.62 | +6.7% |
| EPS, basic (₹) | 18.91 | 14.62 | +29.3% | 17.73 | +6.7% |
| Net margin (%) | 28.1 | 27.9 | 27.7 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,718.39 | 1,376.24 | +24.9% | 1,656.48 | +3.7% |
| Other income | 22.85 | 76.52 | −70.1% | 19.68 | +16.1% |
| Total income | 1,741.24 | 1,452.76 | +19.9% | 1,676.16 | +3.9% |
| Profit before tax | 652.18 | 475.22 | +37.2% | 629.96 | +3.5% |
| Net profit for the period | 487.93 | 391.80 | +24.5% | 461.24 | +5.8% |
| EPS, basic (₹) | 18.38 | 14.76 | +24.5% | 17.37 | +5.8% |
| Net margin (%) | 28.4 | 28.5 | 27.8 |
Consolidated
- Filed with BSE
- 29 May 2021, 18:53 IST
- Board meeting
- 29 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 May 2021, 18:53 IST
- Board meeting
- 29 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE